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Abstract
Background
The incidence of multi-drug resistant ESBL-associated urinary tract infections (UTIs) is
increasing globally. Patients with abnormal renal tract anatomy and other co-morbidities are
at increased risk of complicated UTI and ESBL-associated infections. The duration and
safety of OPAT for this cohort of patients is unknown.
Objectives
This study aims to provide an evidence base to support decision-making regarding duration
of antibiotic treatment for complicated UTIs.
Methods
We retrospectively reviewed all patients receiving ertapenem with or without adjunctive fos-
fomycin for complicated UTIs in the OPAT service of our tertiary infectious diseases hospi-
tal. All data had been collected prospectively as part of routine clinical care. Our primary
outcomes were microbiological and clinical cure of UTI.
Results
We identified 33 treatment episodes of ertapenem use for UTIs. 76% episodes related to
pyelonephritis or urosepsis diagnoses. Renal tract abnormalities or prior urological surgery
were present in 45% of patients. The median duration of appropriate parenteral antibiotic
therapy in our study was 6 days. Clinical cure was achieved with short-course parenteral
treatment alone in 81% of patients and this increased to 96% when adjunctive fosfomycin
was used. There was a single treatment failure resulting in hospital admission.
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Conclusions
Short duration ertapenem via OPAT with or without adjunctive fosfomycin is safe and effec-
tive for the treatment of complicated UTIs. Further studies are required to inform optimal
treatment strategies and publication of guidelines in this field.
Introduction
Antimicrobial resistance (AMR) is associated with increased morbidity, mortality and pro-
longed hospital admission [1, 2]. A major challenge for contemporary health services is the
provision of antimicrobial therapy against resistant organisms that is effective, acceptable to
patients and cost-effective. Outpatient parenteral antibiotic therapy (OPAT) facilitates the
administration of injectable agents to patients outside of hospital who would historically have
required prolonged hospital admission. Both patients and health care providers may benefit
from shortening in-hospital stays and transferring care into a community or outpatient setting
[3].
There is an increasing incidence of community- and hospital-acquired multi-drug resistant
extended spectrum beta-lactamase (ESBL)-associated urinary tracts infections (UTIs) [4]. Car-
bapenems are often used as first line therapy for individuals requiring injectable agents [5].
Once daily ertapenem is emerging as a pragmatic and well-tolerated choice for OPAT in this
setting if there is no other indication for hospital admission [6]. Alongside carbapenems there
is growing use of older-agents such as fosfomycin for the treatment of ESBL UTIs [7]. Cur-
rently UK marketing authorisation of fosfomycin is restricted to oral therapy for acute lower
uncomplicated UTIs but there is increasing interest in using fosfomycin as an oral adjunct or
an alternative intravenous drug for the treatment of complicated UTIs including those associ-
ated with bacteraemia [8, 9]. There are very limited data regarding oral fosfomycin use for this
latter group in the UK and no prospective studies [10].
There remains a paucity of high-quality randomized control trial (RCT) data to guide dura-
tion of antimicrobial therapy for upper tract UTIs. European guidelines advocate up to 21 days
of antimicrobial therapy for complicated UTIs [11]. In the setting of uncomplicated UTIs,
meta-analyses have published conflicting findings regarding efficacy of short course therapy
lasting less than 14 days compared with long courses lasting 14 days or more [12, 13]. Shorten-
ing antibiotic treatments may have significant benefits to antimicrobial stewardship, cost and
patient experience if it can be achieved without compromising clinical care.
History of urological surgery is an independent risk factor for ESBL-associated UTIs [14] (.
This may be associated with an increasingly elderly patient population with multiple co-mor-
bidities undergoing ever-more complex surgery [15, 16]. Surgical patients with complicated
UTIs are underrepresented in the existing OPAT literature [6, 17].
In this study we retrospectively reviewed the clinical and microbiological outcomes of a
prospectively enrolled cohort of patients receiving ertapenem with or without adjunctive fosfo-
mycin via OPAT for UTI.
Materials and methods
The study included patients managed through the OPAT service at University College London
Hospitals (UCLH), a tertiary referral centre in London, United Kingdom. At UCLH patients
are accepted onto the OPAT service after clinical review by at least one infection consultant on
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any day of the week. Consequently, all OPAT patients are clinically reviewed and outcomes
determined weekly by a multidisciplinary team, including at least two infection specialists.
Treatment decisions including selection of appropriate antimicrobials, length of treatment
and addition of oral therapy following OPAT are made by the OPAT MDT. Provision of treat-
ment is most frequently by nursing staff in the patient’s own home although occasionally
patients come to UCLH itself for daily administration of OPAT.
Data collection
We included any patient who completed a course of ertapenem with or without fosfomycin
through OPAT for a UTI over a 16-month period between January 2015 and August 2016.
Demographic, clinical and microbiological data were collected prospectively into an electronic
database used to manage all patients seen by the infectious diseases inpatient and OPAT ser-
vice [18].
Diagnostic investigations
A urine sample was collected from all patients as part of routine clinical management. Analysis
included the presence or absence of leucocytes and nitrites. Bacterial colonies grown on solid
agar plates were identified by MALDI-TOF. Antibiotic susceptibility testing was performed by
the disc diffusion method and Vitek in line with EUCAST recommendations. Blood cultures
and renal tract imaging were collected at the discretion of the clinical team.
Treatment and outcome definitions
Urinary tract infections were classified as complicated or uncomplicated in line with the Euro-
pean Urology Association (EUA) Urological Infection guidelines [11]. Complicated infections
were defined as any infection associated with a risk factor that increased the likelihood of treat-
ment failure. For the purposes of this study we did not consider AMR alone as defining a com-
plicated UTI.
We defined 14 days as standard antibiotic treatment duration for pyelonephritis and acute
bacterial prostatitis, and 28 days for chronic bacterial prostatitis as suggested by EUA guide-
lines to calculate days of treatment saved. This is an intentionally conservative definition. We
did not include patients diagnosed with urosepsis defined by EUA guidelines in the calculation
of days of treatment saved, as treatment guidelines for this diagnosis recognise the heterogene-
ity of such patients and do not mandate treatment duration. Adjunctive fosfomycin is defined
as fosfomycin therapy following initial ertapenem treatment and was considered when the
patient had not achieved clinical cure at the end of their course of ertapenem. Inappropriate
antibiotic use was defined as use of agents to which isolated organisms were proven to be resis-
tant on culture taken at the start of or during the episode of antibiotic therapy. Ertapenem and
Fosfomycin were both prescribed at a standard dose of 1g once a day intravenously and 3g
orally once every three days respectively.
Microbiological cure was defined as a negative culture on any occasion after treatment.
Clinical cure was defined as complete resolution of symptoms and signs of UTI. Treatment
episodes characterised by adverse drug reactions in addition to change of therapy, hospital re-
admission due to UTI or mortality were considered treatment failures.
Ethics
The study was reviewed and approved by the Audit and Research Committee at the Hospital
for Tropical Diseases, University College Hospital. The stated that as this was a retrospective
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case note review, meeting the NHS definition of service evaluation, formal ethical approval
was not required.
Results
OPAT referrals
A total of 30 patients received 33 treatment courses of ertapenem during the period of the
study. The mean age of the cohort was 49 years (range 22–91) and 43% of patients were male.
Acute pyelonephritis was the most common OPAT referral indication (57.6%). Almost half of
the cohort had abnormal renal tracts or prior urological surgery (45%) and one third had risk
factors for a complicated UTI as defined by EUA guidelines. Almost all patients were referred
from inpatient services (82%), most commonly infectious diseases (50%) and urology (27%)
(Table 1)
Microbiology and investigations
Bacteria were isolated in 79% (26/33) of treatment episodes. Of these, 21 patients had a positive
mid-stream urine and 5 patients had a positive blood culture. All patients without positive
samples during the index treatment episode had urinary specimens in the preceding 12
months that had grown ESBL-producing isolates. Bacteria were identified from blood culture
in 5 patients (5/33, 15%). ESBL-producing organisms accounted for 92% of isolates (24/26),
with Escherichia coli being the most common ESBL producer (83%). Klebsiella pneumoniae
was the next most common organism (n = 3, 12%). Two patients with non-ESBL-producing
UTIs required parenteral ertapenem therapy in the absence of oral therapeutic options owing
to drug allergy. Of the ESBL-producing isolates 83% (20/24) were sensitive to fosfomycin
(Table 1). Renal tract imaging was performed in 66% of patients (20/33).
Treatment
In 12 (12/33, 36%) cases, isolated organisms were resistant to initial antimicrobial therapy,
most commonly cefuroxime, the first-line antimicrobial for upper-tract UTIs at UCLH. The
Table 1. Clinical and microbiological characteristics of patients.
Age in years
(Mean and Range)
49 (22–91)
Male 13 (43%)
Indication Pyelonephritis 19 (57.6%)
Urosepsis 6 (18.2%)
Urinary Tract Infection 5 (15.2%)
Prostatitis 3 (9.0%)
Microbiology ESBL E.coli 20 (60.6%)
Other ESBL 2 (6.1%)
AmpC Producer 2 (6.1%)
Other 2 (6.1%)
No positive sample� 7 (21.1%)
Microbiology for patients receiving OPAT ertapenem ESBL/AmpC Producer 31 (93%)
Drug Allergy 2 (7%)
� All patients without a positive microbiology sample during the OPAT episode of care had a previous ESBL isolate
within the previous 12-month period.
https://doi.org/10.1371/journal.pone.0223130.t001
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mean duration of inappropriate antibiotic use was 3 days prior to switching (range 1 to 5
days). The median time from initial treatment to OPAT referral was 3 days (IQR 1–4 days).
For patients diagnosed with pyelonephritis or urosepsis the median duration of appropriate
injectable antibiotic therapy was 6 days (range 3 to 15 days). 72% of this group had compli-
cated UTIs (18/33). The mean duration of OPAT ertapenem in this group was 6 days (range 2
to 9 days). For 63% of treatment episodes (21/33) all antibiotics were delivered through periph-
eral cannulae alone. Adjunctive fosfomycin was used following ertapenem for 6 treatment epi-
sodes (18.2%) 117 treatment days were saved in 22 individuals with upper tract UTIs
(excluding urosepsis) compared with the duration of therapy had standard treatment courses
in line with European guidelines been prescribed.
Outcomes
All patients were reviewed within 7 days of completing OPAT. Clinical cure was seen in 81%
of treatment episodes (27/33) following treatment with ertapenem alone. All patients receiving
adjunctive fosfomycin achieved clinical cure, and therefore including these patients, the overall
cure rate was 97% (32/33 patients). There was one treatment failure where a patient required
readmission to hospital with urosepsis. Two intravenous catheter extravasation injuries
occurred during OPAT resulting in change of intravenous catheters. There were no recorded
adverse drug reactions and no episodes of Clostridium difficile.
Discussion
In this study we provide data to support the use of short courses of ertapenem and adjunctive
fosfomycin delivered though an OPAT service for the treatment of ESBL-associated compli-
cated UTIs. The mean duration of appropriate injectable antimicrobial therapy for the diagno-
ses of pyelonephritis or urosepsis was 7 days. Overall, we were able to successfully limit
treatment duration to 7 days in 81% of patients and achieve clinical cure overall in 96% of
patients. The duration of treatment in this study is significantly shorter than the minimum
duration of antimicrobial therapy suggested by international guidelines for complicated UTIs
and that delivered in other cohort studies [6, 11, 17] and suggests that treatment duration may
be shortened whilst maintaining clinical outcomes. Besides its efficacy and tolerability, the
shorter courses of parenteral therapy delivered in our study reduced the need for long line
indwelling intravascular catheters which are associated with an increased rate of complications
[19].
The current UK licence for fosfomycin is limited to acute lower uncomplicated UTIs. In
this study adjunctive fosfomycin increases the clinical cure rate of complex urinary tract infec-
tions. Whether fosfomycin could be used as an initial or single carbapenem sparing treatment
for complex ESBL UTIs requires further study [9].
The main limitation of the study is the relatively small size of the cohort studied and the
non-randomised nature of the study. The majority of patients had 2 or more risk factors for
complicated UTIs and 45% had abnormal renal tracts, although this was performed at the dis-
cretion of clinicians, possibly introducing bias in our cohort. Nevertheless, complicated UTIs
constitute a growing proportion of OPAT cases but are often excluded from trials, and there-
fore our data add to the efficacy and safety evidence for OPAT ertapenem and fosfomycin to
treat urological infections.
Duration of treatment is a balance between efficacy and tolerability. A formal randomised
trial to compare longer and shorter durations of antibiotics in this setting should be considered
to provide definitive data on optimal treatment duration [20]. Additional studies on the use of
fosfomycin in this setting are warranted. Our data suggest that short courses of parenteral
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ertapenem with or without adjunctive fosfomycin delivered via OPAT is an effective, safe and
cost-effective strategy for managing these infections.
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